Alector Stock Forecast
NASDAQ: ALECHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 1:25 PM ET
ALEC analyst consensus
Consensus (7 analysts)
hold
Avg. price target
$3.30+56.35%
- Strong buy 0
- Buy 3
- Hold 2
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Alector (2026-10-09), 3 rate the stock a buy or strong buy, 2 rate it a hold and 2 rate it a sell or strong sell, for a consensus rating of "hold". The average 12-month price target is $3.30, with a high estimate of $6.00 and a low estimate of $1.00. The average target implies upside of 56.3% from the current price of $2.11.
The spread between the highest and lowest targets is 500.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ALEC.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 43% |
| Hold | 2 | 29% |
| Sell | 1 | 14% |
| Strong sell | 1 | 14% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $1.00 | -52.62% |
| Average target | $3.30 | +56.35% |
| High target | $6.00 | +184.27% |